Corcept Therapeutics

Corcept Therapeutics is a commercial-stage pharmaceutical company that discovers, develops and markets medications for severe endocrinologic, oncologic, metabolic and psychiatric disorders by targeting the effects of cortisol modulation. Its first commercial product is Korlym (mifepristone), which treats hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. The company also has a pipeline of proprietary selective cortisol modulators, including relacorilant, in clinical development.